Pfizer Inc. (PFE.US) wins Paxlovid patent infringement case, Enanta (ENTA.US) plans to appeal.

Enanta Pharmaceuticals (ENTA.US) said on Tuesday that it will appeal to the US Federal Court in support of Pfizer Inc. (PFE.US) in a patent infringement case related to the antiviral drug Paxlovid for COVID-19. The patent dispute between the two companies began in 2022 when Enanta sued Pfizer Inc. in a Massachusetts federal court for alleged infringement of its US Patent No. 11358953 in the manufacturing, use, and sale of Paxlovid. The company stated that in the ruling on Pfizer Inc.'s motion for summary judgment, the court found its 11358953 patent invalid. Enanta added that it will appeal to the US Court of Appeals. CEO Jay Luly said, "We are disappointed by the court's ruling. We firmly believe in the merits of our case, and through the appeals process, we will continue to defend our invention and prevent unlawful infringement."